|

Lecanemab vs Donanemab: Why the Amyloid Target Matters

Clinical Review · Anti-Amyloid Therapy · For Clinicians

Lecanemab vs Donanemab: Why the Amyloid Target Matters

By Brian Paquette, DO, MPH

Lecanemab preferentially binds soluble aggregated amyloid-β protofibrils; donanemab binds pyroglutamate-modified amyloid concentrated in established plaque. That single difference helps explain their different dosing, stopping rules, and MRI schedules — but it does not make either drug categorically more effective.

The clinical problem

Lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid monoclonal antibodies for patients with mild cognitive impairment or mild dementia due to Alzheimer disease and confirmed amyloid pathology. Both substantially lower cerebral amyloid and modestly slow decline over 18 months.[1,2] Clinicians choosing between them need to understand how they differ in the amyloid species recognized, treatment cadence, stopping strategy, and MRI surveillance — differences that matter most when counseling APOE ε4 carriers, who face a higher risk of amyloid-related imaging abnormalities (ARIA). Neither drug reverses established cognitive impairment or cures Alzheimer disease.

Clinical comparison

Feature Lecanemab (Leqembi) Donanemab (Kisunla)
Preferred amyloid target Soluble aggregated Aβ, particularly protofibrils; also binds fibrillar plaque Aβ N-terminally truncated pyroglutamate Aβ (N3pG-Aβ), concentrated in deposited plaques
Studied population Early symptomatic AD: MCI or mild dementia with confirmed amyloid pathology Early symptomatic AD with confirmed amyloid pathology; the pivotal trial also required tau PET criteria
Pivotal phase 3 result CLARITY AD: CDR-SB −0.45 at 18 months (~27% less decline) TRAILBLAZER-ALZ 2, overall: ~22% less decline on iADRS, ~29% on CDR-SB; greater in low/medium tau
Initial schedule 10 mg/kg IV every 2 weeks for 18 months IV every 4 weeks, titrated 350 → 700 → 1,050 → 1,400 mg
After initiation Maintenance: 10 mg/kg IV every 4 weeks, or 360 mg subcutaneous weekly (Leqembi Iqlik autoinjector) May stop once amyloid PET shows reduction to a prespecified low level
ARIA in pivotal trials ARIA-E 12.6%; ARIA-H 17.3% ARIA-E ~24%; ARIA-H ~31% (original titration)
Scheduled MRI Baseline; before infusions 3, 5, 7, and 14; unscheduled if symptoms suggest ARIA Baseline; before infusions 2, 3, 4, and 7; unscheduled if symptoms suggest ARIA
APOE ε4 implication ARIA risk higher in carriers, highest in homozygotes; genotype should inform counseling Same class effect; genotype should inform counseling

Percent slowing is endpoint- and population-dependent. These trials were not a head-to-head comparison, so differences in percentages do not establish superiority. Dosing and MRI schedules per current U.S. labels.[9]

Members Only

This review continues for members

The remainder of this article — the full clinical reasoning, evidence-strength tables, and complete reference list — is available to APOE4 Insights members.

  • Physician-authored, evidence-calibrated clinical reviews
  • Explicit about what the data do and do not support
  • No industry sponsorship, no supplement affiliates

$79 a year, with a 7-day free trial and a 30-day money-back guarantee. Founding members: $59/year with code FOUNDING.

Become a Member

Already a member? Log in

Similar Posts